Navigation Links
Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
Date:10/12/2009

in(TM) be completed prior to regulatory approval. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion being unsuccessful in achieving its strategic alternatives, including any combination of a restructuring of the Company and its debt, a sale of the Company or its assets, and raising new capital, in which case it may have to consider curtailing or ceasing operations or liquidating its assets, Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin(TM) (laromustine) Injection, delays in the regulatory approval process, particularly for Onrigin(TM) (laromustine) Injection, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, including the need for a new randomized trial of Onrigin(TM) prior to regulatory approval in accordance with the recommendation of the Oncologic Drug Advisory Committee, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, ... delighted to announce that the Malcolm Campbell Memorial ... (Vice President of Chemistry), Fiona Marshall (Chief ... Executive Officer and co-founder) for the seminal contributions to GPCR ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Corporation (Nasdaq: DNDN ) announced today that ... remainder of its New Jersey manufacturing facility, allowing the ... to help meet the needs of patients with asymptomatic ... cancer.   Last April, upon receiving FDA ...
... Hospital and SynCardia Systems, Inc. announced today that Texas ... complete the first phase of certification to implant the ... use the Total Artificial Heart as a bridge to ... as children and now require mechanical support as a ...
Cached Medicine Technology:Dendreon Expands Launch of PROVENGE 2Dendreon Expands Launch of PROVENGE 3Dendreon Expands Launch of PROVENGE 4Dendreon Expands Launch of PROVENGE 5Texas Children's Is First Pediatric Hospital To Begin Certification Process for SynCardia's Total Artificial Heart 2Texas Children's Is First Pediatric Hospital To Begin Certification Process for SynCardia's Total Artificial Heart 3
(Date:1/23/2015)... AZ (PRWEB) January 23, 2015 Hastings and ... injury matters, reports a record number of legal representation client ... speaking, there has been a steady rise in the number ... work and at home throughout the Valley. With that said, ... accident be reviewed by an experienced law firm. Hastings and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Liberty University has ... (M.A.) program from the Council for Accreditation of ... part of Liberty’s Center for Counseling & Family Studies ... dean of the university’s new School of Behavioral Sciences. Prior ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located in ... number one best large hotel for families in the United ... annual Travelers’ Choice Awards. , TripAdvisor represents the world’s ... to millions of unbiased and honest traveler reviews. The best ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader ... designers are thrilled to have it lead the wedding dress ... collection of prom dresses for the global market. , “The ... vision and he focuses on continuing the goal of operational ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... be very high , , WEDNESDAY, Sept. 26 (HealthDay News) ... as Tylenol), taken together, could lead to liver damage, ... that,s toxic to the organ, researchers from the University ... not only by drinking caffeine while taking acetaminophen, the ...
... the Largest Independent Ecolabel in the U.S., ... GS-8, Green Seal,s Environmental Standard for Household Cleaners.,The ... ever-increasing,discoveries about the detrimental effects of certain chemicals ... last year that GS-8 required,revision. Now available to ...
... Industry Advisors and ... ... Inc., developers,of the G-Trainer anti-gravity treadmill, today announced advisor,relationships with ... treadmill manufacturer. Alter-G,s anti-gravity treadmill, the G-Trainer, enables users ...
... Chaka Fattah votes in favor of health insurance for low-income ... ... Congressman Chaka,Fattah (D-PA) joined with a bi-partisan coalition of his colleagues ... income,children. "For years I have been a supporter of both The ...
... 25 Gentiva Health,Services, Inc. (Nasdaq: GTIV ... and related services, today announced that it has,filed ... and,Exchange Commission (SEC) for the periodic offering and ... preferred stock, common stock and warrants,after the SEC ...
... 25 Haemonetics,Corporation CEO, Brad Nutter, will be ... September 26, 2007 at 2:30 pm. Mr. Nutter,s,presentation ... The webcast will be,available for replay through October ... During the presentation, Mr. Nutter will give an ...
Cached Medicine News:Health News:Caffeine Plus Acetaminophen Toxic for Some 2Health News:Green Seal Ramps Up Environmental Standard for Household Cleaners 2Health News:Alter-G Forging New Relationships 2Health News:Alter-G Forging New Relationships 3Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 3Health News:Haemonetics' Webcast Presentation 2
The compact, simple-to-use ECG for medical professionals....
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
The ideal on-the-spot reference for residents and practitioners seeking fast facts on fracture management....
Medicine Products: